Immunohistochemistry testing also identified 49 patients (4.1%) with tumor ALK fusions among 1202 patients who underwent testing, and 16 patients (1.1%) had ROS1 rearrangements confirmed by FISH. This evidence concerns the gene ALK and neoplasm.